Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting

Abstract

B-type natriuretic peptide blood concentration measurement appears to be a sensitive and specific test to diagnose CHF in urgent-care settings.

Low Homoarginine Levels in the Prognosis of Patients With Acute Chest Pain

“…No deviations from this assumption were found. Patients were divided into 2 BNP groups using a cut‐off value of 80 pg/mL as a predictor of the presence of congestive heart failure,22 and the homoarginine cutoff was used to produce survival curves on each BNP group. The log‐rank test was used to test for differences.…”

Comparison of Enzymatic Recycling Electrodes for Measuring Aminophenol: Development of a Highly Sensitive Natriuretic Peptide Assay System

“…31 However, we consider that the present RSD values would be acceptable for on-site monitoring of natriuretic peptide for clinical diagnosis, because the peptide concentration in blood significantly increases in heart failure patients. 11,12 Recovery tests of spiked samples with ANP To explore the applications of the present method, we performed recovery tests for ANP spiked in human serum. The human serum was a 1:5 diluted sample that was filtered before the measurement.…”

“…[4][5][6][7][8][9][10] The concentrations of ANP and BNP in our blood under normal conditions are extremely low (< 40 pg mL -1 (ppt)), but rise to by 10 -100 fold in patients with severe congestive heart failure. 11,12 To measure such low concentrations of peptides, recearchers have developed and commercialized highly-sensitive radioimmunoassays or enzyme immunoassays based on chemiluminescence or fluorescence. [13][14][15][16] However, simple and inexpensive bedside measurements in ambulances, hospitals, and homes are difficult to accomplish with these methods, because the aforementioned methods require expensive and massive apparatuses.…”

Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure

“…Brain (B-type) natriuretic peptide (BNP) has emerged in recent years as an effective diagnostic and prognostic cardiac biomarker for HF (4)(5)(6)(7)(8)(9)(10). Commercially available point-of-care tests (POCTs) have been developed for rapidly determining BNP levels in patients and have found widespread use in clinics, hospitals, and urgent-care facilities worldwide (10)(11)(12).…”

“…Commercially available point-of-care tests (POCTs) have been developed for rapidly determining BNP levels in patients and have found widespread use in clinics, hospitals, and urgent-care facilities worldwide (10)(11)(12). These tests provide invaluable, real-time diagnostic information to health-care deliverers who can quickly diagnose patients presenting with HF symptoms (e.g., shortness of breath, chest pain) (5,7). After diagnosis, the POCT has been used as a costeffective means for monitoring HF treatment efficacy.…”